Advertisement
New review sorts evidence from overgeneralizations
When it comes to teasing out the effects of dietary carbohydrate intake on cardiometabolic health, the devil is very much in the details, and more details are needed for conclusions on some important questions. That’s an overarching message of a new evidence-based review of the topic published in Atherosclerosis (Epub March 27, 2021) by Cleveland Clinic cardiologist Leslie Cho, MD, and two European colleagues.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“Carbohydrates have been vilified in the media over the past two decades, often due to overbroad generalizations not supported by evidence,” says Dr. Cho, Co-Section Head of Preventive Cardiology and Rehabilitation. “The recent prominence of high-protein diets for weight loss has fueled further confusion, leading too many people to overlook the essential role carbohydrates play in a healthy diet.”
Together with expert nutrition and health researchers from the Netherlands and Italy, Dr. Cho reviewed the latest evidence — almost exclusively from observational studies and meta-analyses of intervention studies — on the effect of fiber, whole grain and refined carbohydrates on the following:
They begin by noting that current understanding of carbohydrates’ health effects has been hindered by the traditional limitations of dietary recall studies and the fact that many studies to date have failed to differentiate among the various types of carbohydrates.
“Carbohydrates may be thought of in terms of complex versus simple and then further broken down into fiber, starches and sugar,” notes Dr. Cho, the paper’s corresponding author.
Accordingly, the paper proceeds to review the latest evidence from clinical studies in three main sections:
The review leads the authors to a number of conclusions, including the following:
Advertisement
“The quality of the carbohydrate dictates its effect on both cardiometabolic health and cardiovascular events,” observes Dr. Cho. “Moreover, individuals’ responses to dietary fiber interventions are likely determined by their initial microbial and/or metabolic phenotype. It’s becoming more and more clear that this is not a one-size-fits-all question.”
In fact, the review authors identify the impact of individual traits and lifestyle factors on the effectiveness of fiber interventions as a priority for future research. Another priority focus is the role played by regional and ethnic differences in various metabolic and clinical outcomes of the consumption of differing types of carbohydrates. And the authors note that because most data to date are from observational studies, definitive evidence on the benefits and adverse effects of various carbohydrate types is lacking.
The review authors note that the emergence of mobile app-enabled patient-entered diet data should help bolster the number and quality of dietary and intervention studies to start filling these knowledge gaps. “A revolution in dietary research may be at hand, thanks to the power of patient-entered data along with evolving insights into the impact of the gut microbiome,” says Dr. Cho.
In the meantime, despite the considerable remaining uncertainties, she believes there’s enough clarity to make a broad recommendation for present action. “At a global level, most people consume less than 20 grams of fiber daily while consuming a large quantity of refined carbohydrates,” Dr. Cho notes. “The current evidence fully justifies additional measures to enhance the amount and diversity of fiber consumption worldwide while simultaneously reducing intake of refined carbohydrates.”
Advertisement
The review paper is available here.
Advertisement
Advertisement
Phase 2 trial of zerlasiran yields first demonstration of longer effect with each dose of an siRNA
Metabolites from animal product substrates implicated in heart failure development in community cohorts
Studies reveal increased cardiac events, enhanced platelet reactivity and thrombotic potential
Reassurance from the lipid outcomes trial with the highest percentage female enrollment to date
Tech-assisted self-selection concurred with clinician-assessed eligibility in >90% of cases
Newly identified pathway may explain the so-called niacin paradox
It's time to increase testing for this major cardiovascular risk factor in advance of new therapies
Findings establish overweight/obesity as a modifiable risk factor for cardiovascular disease